We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

14 hedge funds and large institutions have $415K invested in Phio Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

17% more funds holding

Funds holding: 12 → 14 (+2)

0% less ownership

Funds ownership: 0.05% → 0.05% (-0%)

25% less capital invested

Capital invested by funds: $551K → $415K (-$136K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
14
Holders Change
+2
Holders Change %
+16.67%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
4
Closed
1
Calls
$36K
Puts
–
Net Calls
+$36K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$12.8K
2
E
Ergoteles
New York
+$8.71K
3
TSS
Two Sigma Securities
New York
+$8.48K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$7.04K
5
VF
Virtu Financial
New York
+$2.88K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$56K
2
Renaissance Technologies
Renaissance Technologies
New York
-$14.9K
3
Two Sigma Investments
Two Sigma Investments
New York
-$3.18K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.89K
5
Simplex Trading
Simplex Trading
Illinois
-$303

PHIO Hedge Fund Activity: Q3 2022 in Review

14 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2022, worth a combined $415K — down 25% from $551K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PHIO positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $12.8K. The largest seller was Vanguard Group, cutting an estimated $56K.

  • 14 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2022, up from 12 in Q2 2022.
  • Funds reported $415K of Phio Pharmaceuticals stock for Q3 2022, down 25% quarter-over-quarter.
  • 3 funds opened new Phio Pharmaceuticals positions in Q3 2022 and 1 closed out, a net change of +2 holders.
  • The largest Phio Pharmaceuticals buyer in Q3 2022 was HRT Financial, an estimated $12.8K added.
  • The largest Phio Pharmaceuticals seller in Q3 2022 was Vanguard Group, an estimated $56K sold.

Based on aggregated 13F filings for Q3 2022.